Resources Repository
-
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | Health/Medicine | Global | Policy/Regulation | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Economics/Finance | North America -
ArticlePublication 2017Estimating the Fitness Cost and Benefit of Cefixime Resistance in Neisseria Gonorrhoeae
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more …
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more than half of annual infections occur in men who have sex with men (MSM). As the bacterium has developed resistance to each first-line antibiotic in turn, an improved understanding is needed of fitness benefits and costs of antibiotic resistance to inform control policy and planning. The authors developed a stochastic compartmental model representing the natural history and transmission of cefixime-sensitive…
Decision Analysis | Health/Medicine | Global | Policy/Regulation | Infectious Diseases | Dynamic Transmission | Risk Analysis | Health Systems | Government/Law | Science/Technology -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Benefit-Cost Analysis | Health/Medicine | Global | Mental Health | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Calibration/Validation | Health/Medicine | Latin America & Caribbean | Global | Infectious Diseases | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean
This article reports on a model-based approach estimated averted cervical cancer cases and deaths, disability-adjusted …
This article reports on a model-based approach estimated averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for human papillomavirus (HPV) vaccination of young adolescent girls using population and epidemiologic data for 33 countries in Latin America and the Caribbean (LAC). The authors found that an absolute reduction in lifetime cancer risk varied between countries, depending on incidence, proportion attributable to HPV-16 and 18, and population age-structure; for…
Calibration/Validation | State-Transition | Health/Medicine | Latin America & Caribbean | Infectious Diseases | Costing Methods | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Economics/Finance | Science/Technology -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
State-Transition | Health/Medicine | Global | Infectious Diseases | Test Performance | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | North America -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
State-Transition | Health/Medicine | Latin America & Caribbean | Infectious Diseases | Health Outcomes | Dynamic Transmission | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Economics/Finance | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2017Likelihood Approach for Calibration of Stochastic Epidemic Models
Stochastic transmission dynamic models are especially useful for studying the early emergence of novel pathogens …
Stochastic transmission dynamic models are especially useful for studying the early emergence of novel pathogens given the importance of chance events when the number of infectious individuals is small. However, methods for parameter estimation and prediction for these types of stochastic models remain limited. This paper describes a calibration and prediction framework for stochastic compartmental transmission models of epidemics. The proposed method applies a linear noise approximation to describe the size of the fluctuations, and…
Calibration/Validation | Health/Medicine | Global | Infectious Diseases | Dynamic Transmission | Dynamic Simulation | Health Systems -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
State-Transition | Health/Medicine | Latin America & Caribbean | Infectious Diseases | Health Outcomes | Mathematical Models | Dynamic Transmission | Microsimulation | Global Governance | Economics/Finance | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific